Votrient (Pazopanib) 400 mg
Votrient is the originator brand of the targeted therapy drug Pazopanib (400 mg).
Manufacturer: GlaxoSmithKline (GSK) / Novartis. This is the FDA-approved reference product used in global clinical trials.
Mechanism of Action:
Votrient is a potent multi-kinase inhibitor. It halts cancer progression by inhibiting angiogenesis — blocking the formation of new blood vessels that tumors need to grow and spread.
✅ Why choose the Original? Guaranteed quality, stability, and proven efficacy profile for patients seeking the best available care.
Approved for the treatment of:
- Advanced Renal Cell Carcinoma (RCC): Standard first-line treatment for kidney cancer.
- Advanced Soft Tissue Sarcoma (STS): For patients who have received prior chemotherapy.
Strength: 400 mg tablet.
Standard Dosage: 800 mg (two 400 mg tablets) taken once daily.
⚠️ CRITICAL WARNING - EMPTY STOMACH:
- 🚫 Take at least 1 hour before a meal.
- 🚫 Or take at least 2 hours after a meal.
Danger: Food increases systemic exposure to pazopanib, potentially leading to severe liver toxicity. Tablets must be swallowed whole; do not crush.
- Severe hepatic impairment.
- Pregnancy (Category D).
- Children under 2 years of age (risk of severe organ toxicity).
Notable side effects include:
- Hair Depigmentation: Hair turning white or grey is a common, harmless side effect.
- Hepatotoxicity: Regular monitoring of liver enzymes (ALT, AST, Bilirubin) is mandatory.
- Hypertension: Monitor blood pressure.
- Diarrhea and fatigue.
What Customers Say
No reviews yet
Your review can be the first!